Fair Value Measurements

3 Months Ended

Mar. 31, 2023

8. Fair Value Measurements

The following table presents information about the Company’s derivative liabilities that are measured at fair value on a recurring basis as of March 31, 2023 and December 31, 2022 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value.


	As of March 31, 2023
	Level 1		Level 2		Level 3		Total
Liabilities:
Warrants	$	1,416,667	$	—	$	—	$	1,416,667
Private Placement Warrants		—		793,333		—		793,333
Total	$	1,416,667	$	793,333	$	—	$	2,210,000

	As of December 31, 2022
	Level 1		Level 2		Level 3		Total
Liabilities:
Warrants	$	666,667	$	—	$	—	$	666,667
Private Placement Warrants		—		373,333		—		373,333
Total	$	666,667	$	373,333	$	—	$	1,040,000

The following table presents the changes in the fair value of the Company’s derivative liabilities that are measured at fair value for the three months ended March 31, 2023 and 2022.


	Warrants			Private Placement Warrants			Total
Liabilities:
Fair value at December 31, 2022	$	666,667		$	373,333		$	1,040,000
Change in fair value		750,000			420,000			1,170,000
Fair value at March 31, 2023	$	1,416,667		$	793,333		$	2,210,000

	Warrants			Private Placement Warrants			Total
Liabilities:
Fair value at December 31, 2021	$	5,833,333		$	3,266,667		$	9,100,000
Change in fair value		(2,333,333	)		(1,306,667	)		(3,640,000	)
Fair value at March 31, 2022	$	3,500,000		$	1,960,000		$	5,460,000

The Company did not hold any Level 3 financial instruments as of March 31, 2023 and December 31, 2022 or during the three months ended March 31, 2023 and 2022.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

AfterNext HealthTech Acquisition Corp. 10-Q